In November 2024, Novo Nordisk AS is expected to secure expanded FDA approval for CagriSema, its dual amylin/GLP-1 agonist, for a broader population of patients with type 2 diabetes and high cardiovascular risk
First identified in 2012, it is defined by iron-dependent lipid peroxidation and the accumulation of lipid peroxides (17, 18)
Many patients see the best results when semaglutide GLP-1 is combined with realistic lifestyle changes, such as eating balanced meals, focusing on protein, limiting processed foods, staying hydrated, and adding regular movement
In addition to supporting liver detoxification, boosting glutathione levels will also provide additional antioxidant protection, increase protection against viruses and toxins from mold exposure and give general support to the immune system
So, people injecting tiny doses of a GLP-1 are likely subject to the same effects that the placebo recipients in these studies experienced